Terapia Ranbaxy gets mrkt authorisations for 20 products

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Terapia Ranbaxy gets mrkt authorisations for 20 products

Terapia Ranbaxy gets market authorisations for 20 new products

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy Lab make smart gains Ranbaxy in drug dev deal with US based PPD Ranbaxy Laboratories has support at Rs 350-355 ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited announced today that Terapia Ranbaxy, with a market share of 5.6%, has recently received Market Authorisations (MAs) for 20 new products to be launched in the coming months.  "The list of MAs granted by the National Agency of Medicine refers to products from different therapeutic areas mainly  from the cardiovascular, antibiotics or CNS segments," said Dragos Damian, CEO, Terapia Ranbaxy. "These are either new molecules on the market like Citaloran or unique and modern formulations or concentrationslike  Lamotiran - oral dispersible tablets, Pravator, Quinaran, Terbinaran or Glimeran, among others."

According to Damian these new launches reinforce the Company's promise to bring value-added niche products at affordable prices, to the Romanian pharmaceutical market.

With the commercial department structured in business units, Terapia Ranbaxy employs more than 1,200 people, of which 350 form the largest professional field force in the Romanian pharmaceutical market.

According to the latest market analysis, Terapia Ranbaxy is the biggest generics producer in Romania, outperforming all other similar companies active in the market

In March 2007, Terapia Ranbaxy announced that it had obtained the  new Manufacturing and Import Authorization as per EU norms and standards. As a result, the company is entitled to batch test and release products manufactured outside the European Union. With this development, Terapia Ranbaxy becomes the first pharmaceutical company authorized to batch test and release products in Romania.

In June 2006, Ranbaxy Laboratories Ltd. announced the completion of the acquisition process by Ranbaxy Netherlands BV of 96,7%  of the top Romanian generics company Terapia SA. The combined operations of Terapia Ranbaxy established the largest Romanian generics company. The commercial name of the company is Terapia Ranbaxy.

In November last year, Terapia Ranbaxy announced the completion of the investment in a new logistic center in Otopeni - Bucharest. The investment' was aimed  at increasing the company's warehousing space for all products included in the Terapia Ranbaxy portfolio  and for adding bonded customs warehousing services for the products produced by Ranbaxy and imported from India.

The company is undergoing a successful integration process including re-branding, and training of the commercial force and has registered a 50% growth in 2006 in comparison to the previous year.

Sourced From: Ranbaxy Laboratories Ltd